Kane Biotech Inc. (KNE.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.09 Million CAD | 44.4% |
| 2022 | 9.75 Million CAD | 26.7% |
| 2021 | 7.7 Million CAD | 94.43% |
| 2020 | 3.96 Million CAD | 106.42% |
| 2019 | 1.91 Million CAD | -24.48% |
| 2018 | 2.54 Million CAD | 285.53% |
| 2017 | 659.03 Thousand CAD | -15.91% |
| 2016 | 783.71 Thousand CAD | 13.11% |
| 2015 | 692.86 Thousand CAD | 4.27% |
| 2014 | 664.51 Thousand CAD | 10.69% |
| 2013 | 600.31 Thousand CAD | 239.68% |
| 2012 | 176.72 Thousand CAD | 90.59% |
| 2011 | 92.72 Thousand CAD | 2.18% |
| 2010 | 90.74 Thousand CAD | 32.25% |
| 2009 | 68.61 Thousand CAD | -13.76% |
| 2008 | 79.56 Thousand CAD | -9.44% |
| 2007 | 87.85 Thousand CAD | -5.36% |
| 2006 | 92.83 Thousand CAD | -31.04% |
| 2005 | 134.62 Thousand CAD | 35.0% |
| 2004 | 99.72 Thousand CAD | 74.88% |
| 2003 | 57.02 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 15.33 Million CAD | 8.82% |
| 2024 Q2 | 4.79 Million CAD | -68.72% |
| 2023 Q4 | 14.09 Million CAD | 8.19% |
| 2023 Q1 | 10.88 Million CAD | 11.53% |
| 2023 Q2 | 11.82 Million CAD | 8.68% |
| 2023 FY | 14.09 Million CAD | 44.4% |
| 2023 Q3 | 13.02 Million CAD | 10.12% |
| 2022 Q2 | 9.74 Million CAD | 17.73% |
| 2022 Q1 | 8.28 Million CAD | 7.53% |
| 2022 Q4 | 9.75 Million CAD | -1.67% |
| 2022 FY | 9.75 Million CAD | 26.7% |
| 2022 Q3 | 9.92 Million CAD | 1.78% |
| 2021 Q3 | 6.99 Million CAD | 28.68% |
| 2021 Q1 | 4.15 Million CAD | 4.79% |
| 2021 FY | 7.7 Million CAD | 94.43% |
| 2021 Q2 | 5.43 Million CAD | 30.93% |
| 2021 Q4 | 7.7 Million CAD | 10.13% |
| 2020 Q3 | 2.91 Million CAD | 15.83% |
| 2020 FY | 3.96 Million CAD | 106.42% |
| 2020 Q2 | 2.51 Million CAD | 29.16% |
| 2020 Q4 | 3.96 Million CAD | 35.98% |
| 2020 Q1 | 1.94 Million CAD | 1.47% |
| 2019 Q3 | 2.59 Million CAD | -7.74% |
| 2019 FY | 1.91 Million CAD | -24.48% |
| 2019 Q4 | 1.91 Million CAD | -26.06% |
| 2019 Q1 | 3.26 Million CAD | 28.7% |
| 2019 Q2 | 2.81 Million CAD | -13.98% |
| 2018 Q3 | 1.3 Million CAD | 140.74% |
| 2018 Q2 | 540 Thousand CAD | -35.07% |
| 2018 Q4 | 2.54 Million CAD | 95.44% |
| 2018 FY | 2.54 Million CAD | 285.53% |
| 2018 Q1 | 831.67 Thousand CAD | 26.2% |
| 2017 FY | 659.03 Thousand CAD | -15.91% |
| 2017 Q2 | 1.3 Million CAD | 47.36% |
| 2017 Q4 | 659.03 Thousand CAD | 70.86% |
| 2017 Q3 | 385.7 Thousand CAD | -70.53% |
| 2017 Q1 | 888.08 Thousand CAD | 13.32% |
| 2016 Q1 | 1.13 Million CAD | 64.45% |
| 2016 FY | 783.71 Thousand CAD | 13.11% |
| 2016 Q4 | 783.71 Thousand CAD | 7.95% |
| 2016 Q3 | 726.02 Thousand CAD | 6.76% |
| 2016 Q2 | 680.03 Thousand CAD | -40.32% |
| 2015 Q1 | 660.22 Thousand CAD | -0.64% |
| 2015 FY | 692.86 Thousand CAD | 4.27% |
| 2015 Q3 | 696.77 Thousand CAD | 2.87% |
| 2015 Q4 | 692.86 Thousand CAD | -0.56% |
| 2015 Q2 | 677.35 Thousand CAD | 2.59% |
| 2014 Q3 | 691.08 Thousand CAD | 42.48% |
| 2014 FY | 664.51 Thousand CAD | 10.69% |
| 2014 Q1 | 489.62 Thousand CAD | -18.44% |
| 2014 Q2 | 485.03 Thousand CAD | -0.94% |
| 2014 Q4 | 664.51 Thousand CAD | -3.85% |
| 2013 Q1 | 104.21 Thousand CAD | -41.03% |
| 2013 Q4 | 600.31 Thousand CAD | 355.7% |
| 2013 Q2 | 75.68 Thousand CAD | -27.38% |
| 2013 FY | 600.31 Thousand CAD | 239.68% |
| 2013 Q3 | 131.73 Thousand CAD | 74.05% |
| 2012 Q4 | 176.72 Thousand CAD | 128.17% |
| 2012 FY | 176.72 Thousand CAD | 90.59% |
| 2012 Q1 | 72.09 Thousand CAD | -22.25% |
| 2012 Q2 | 101.04 Thousand CAD | 40.16% |
| 2012 Q3 | 77.45 Thousand CAD | -23.35% |
| 2011 Q1 | 206.55 Thousand CAD | 127.61% |
| 2011 FY | 92.72 Thousand CAD | 2.18% |
| 2011 Q2 | 35.8 Thousand CAD | -82.66% |
| 2011 Q3 | 58.5 Thousand CAD | 63.4% |
| 2011 Q4 | 92.72 Thousand CAD | 58.48% |
| 2010 Q4 | 90.74 Thousand CAD | 21.34% |
| 2010 FY | 90.74 Thousand CAD | 32.25% |
| 2010 Q3 | 74.78 Thousand CAD | 73.52% |
| 2010 Q2 | 43.1 Thousand CAD | -38.36% |
| 2010 Q1 | 69.92 Thousand CAD | 1.91% |
| 2009 Q1 | 46.05 Thousand CAD | -42.12% |
| 2009 FY | 68.61 Thousand CAD | -13.76% |
| 2009 Q4 | 68.61 Thousand CAD | 16.23% |
| 2009 Q3 | 59.03 Thousand CAD | 153.31% |
| 2009 Q2 | 23.3 Thousand CAD | -49.39% |
| 2008 FY | 79.56 Thousand CAD | -9.44% |
| 2008 Q4 | 79.56 Thousand CAD | 34.45% |
| 2008 Q3 | 59.17 Thousand CAD | -57.72% |
| 2008 Q1 | 130.44 Thousand CAD | 48.48% |
| 2008 Q2 | 139.96 Thousand CAD | 7.3% |
| 2007 Q4 | 87.85 Thousand CAD | 22.33% |
| 2007 Q2 | 62.63 Thousand CAD | 36.41% |
| 2007 Q1 | 45.91 Thousand CAD | -50.54% |
| 2007 FY | 87.85 Thousand CAD | -5.36% |
| 2007 Q3 | 71.82 Thousand CAD | 14.66% |
| 2006 Q3 | 93.19 Thousand CAD | -2.11% |
| 2006 Q4 | 92.83 Thousand CAD | -0.39% |
| 2006 Q2 | 95.2 Thousand CAD | -38.32% |
| 2006 Q1 | 154.36 Thousand CAD | 14.67% |
| 2006 FY | 92.83 Thousand CAD | -31.04% |
| 2005 Q2 | 108.38 Thousand CAD | -17.07% |
| 2005 FY | 134.62 Thousand CAD | 35.0% |
| 2005 Q1 | 130.68 Thousand CAD | 31.05% |
| 2005 Q3 | 41.14 Thousand CAD | -62.04% |
| 2005 Q4 | 134.62 Thousand CAD | 227.18% |
| 2004 FY | 99.72 Thousand CAD | 74.88% |
| 2004 Q1 | 81.36 Thousand CAD | 42.69% |
| 2004 Q2 | 32.16 Thousand CAD | -60.47% |
| 2004 Q3 | 5928.00 CAD | -81.57% |
| 2004 Q4 | 99.72 Thousand CAD | 1582.25% |
| 2003 Q2 | 16.93 Thousand CAD | 0.0% |
| 2003 Q3 | 28.42 Thousand CAD | 67.87% |
| 2003 Q4 | 57.02 Thousand CAD | 100.59% |
| 2003 FY | 57.02 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arch Biopartners Inc. | 6.68 Million CAD | -110.902% |
| Covalon Technologies Ltd. | 6.1 Million CAD | -130.695% |
| Hemostemix Inc. | 7.68 Million CAD | -83.348% |
| Universal Ibogaine Inc. | 2.37 Million CAD | -493.36% |
| MedMira Inc. | 18.68 Million CAD | 24.584% |
| Marvel Biosciences Corp. | 2.39 Million CAD | -488.942% |
| NervGen Pharma Corp. | 15.24 Million CAD | 7.575% |
| XORTX Therapeutics Inc. | 1.08 Million CAD | -1193.78% |